As Real-World Evidence will become the new gold standard in patient care, researchers and clinicians have the opportunity to go beyond brief snapshots of data captured by traditional in-clinic assessments to develop new drugs. SYSNAV Healthcare developed Syde, the first digital endpoint platform approved by the European Medicines Agency (EMA) in neuroscience.


Our goal is to quantify patients’ real-life motor functions to:


  • Accelerate clinical trials in rare neurological disease
  • Build more robust conclusions for pivotal clinical trials
  • Collect Real-World Data to generate Real-World Evidence of drug effectiveness

By constantly improving our digital endpoint platform, we provide ever more accurate data through continuous and seamless patient monitoring thanks to a cutting-edge technology developed by SYSNAV Healthcare. Our team is composed of renowned physicians, data science experts, and clinical researchers dedicated to build relevant patient outcomes for mobility assessment.